This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
Submit your application for research grant funding
AST
The AST is now accepting applications for 2015 research grants, including a new AST Transplant Nursing Grant. For 2015, the AST has identified research priorities in the areas of basic science, clinical science, and translational science. View the list of research priorities here or visit www.myast.org to get started on your application. All applications are due by Monday, September 15, 2014.
RSVP for the AST Town Hall Meeting & Excellence in Transplantation Reception at the 2014 WTC
AST
AST members are invited to take part in the annual member's business meeting, delivered in an exciting interactive town hall format. The Town Hall will take place during the upcoming World Transplant Congress (WTC) on Tuesday, July 29, 2014 at 5:45 PM on the second floor foyer of the Moscone West Convention Center. Join your colleagues and AST leadership to discuss the challenges and opportunities in the field of transplantation, learn how AST is positioned to meet these challenges/opportunities, and provide your feedback in shaping the future of the AST.
Immediately following the town hall, enjoy a casual gathering at the AST Excellence in Transplantation Reception, also on the second floor foyer of the Moscone West Convention Center. Indulge in delectable libations and hors d'oeuvres as you mingle with friends, award and grant recipients, and supporters.
Click here to submit your R.S.V.P. to attend both the town hall and reception. Should you have any questions, please do not hesitate to contact the AST staff at info@myAST.org or (856) 439-9986.
We look forward to seeing you in San Francisco!
These events made possible in part by Sanofi and Veloxis Pharmaceuticals
|
UPCOMING EVENTS IN TRANSPLANTATION
|
Register today for the AST 2014 Fellows Symposium
AST
September 19-21, 2014
Grapevine, Texas
Join us this September for the AST Fellows Symposium, a highly popular educational meeting for young professionals starting a career in transplantation or immunology. Featuring an in-depth and interactive study of clinical transplantation, basic transplant immunobiology, and translational science in an informal setting, the Fellows Symposium provides important insights into career development and exceptional access to expert faculty. A limited number of travel grants are available for clinical and research fellows, and residents and trainees with an interest in solid organ transplantation. Register now!
|
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE
|
|
Save the Date for the Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies
AST
February 5-7, 2015
Sheraton Wild Horse Pass – Chandler, AZ
Make plans to attend this high-energy, intimate meeting featuring sessions on:
- A Critical Review of Cell Therapies
- Whatever Happened to Gene Therapy?
- Organ Repair and Regeneration, and Organ Generation
- Drug Development and Rediscovering Pathways
- In vitro, In vivo, and In silico: Are We Done with Animal Models?
Website and call for basic, clinical and translational abstracts coming soon!
PRODUCT SHOWCASE
 |
|
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
|
|
Long-term risks for kidney donors
Kidney International (log in required)
Previous studies have suggested that living kidney donors maintain long-term renal function and experience no increase in cardiovascular or all-cause mortality. However, most analyses have included control groups less healthy than the living donor population and have had relatively short follow-up periods. In the following, researchers compared long-term renal function and cardiovascular and all-cause mortality in living kidney donors compared with a control group of individuals who would have been eligible for donation.
Sixth INTERMACS annual report: A 10,000-patient database
The Journal of Heart and Lung Transplantation (log in required)
The sixth annual report of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) summarizes the first 8 years of patient enrollment. The analysis is based on data from 10,000 patients and updates demographics, survival, adverse events and risk factors. Among patients with continuous-flow pumps, actuarial survival continues to be 80% at 1 year and 70% at 2 years. The report features a comparison of two eras of continuous-flow durable devices in the USA in terms of device strategy, patient profiles, adverse event burden, survival and quality of life.
An easily calculable and highly predictive risk index for postoperative renal failure after heart transplantation
The Journal of Thoracic and Cardiovascular Surgery (log in required)
This 100-point risk index incorporating 13 risk factors is highly predictive of new-onset postoperative renal failure after orthotopic heart transplantation. Prospective assessment of orthotopic heart transplant recipients using the risk categories that were generated on the basis of score ranges may help in tailoring perioperative management.
The immune phenotype may relate to cancer development in kidney transplant recipients
Kidney International (log in required)
High regulatory T-cell (Treg) numbers predict recurrent cutaneous squamous cell carcinoma in kidney transplant recipients, and the Treg immune phenotype may identify kidney transplant recipients at risk of developing squamous cell carcinoma and/or solid-organ cancer. To investigate this, a total of 116 kidney transplant recipients, of whom 65 had current or past cancer, were immune-phenotyped and followed up prospectively for a median of 15 months.
Multimodality therapy and liver transplantation for hepatocellular carcinoma: A 14-year prospective analysis of outcomes
Transplantation (log in required)
Hepatocellular carcinoma is a major cause of death among patients with cirrhosis. A standardized approach of multimodality therapy with intent-to-treat by transplantation for all patients with hepatocellular carcinoma was instituted at our transplant center in 1997. Data were prospectively collected to evaluate the impact of multimodality therapy on posttransplant patient survival, tumor recurrence, and patient survival without transplantation.
Variation in access to the liver transplant waiting list in the United States
Transplantation (log in required)
In the following, researchers sought to compare liver transplant waiting list access by demographics and geography relative to the pool of potential liver transplant candidates across the United States using a novel metric of access to care, termed a liver wait-listing ratio (LWR).
Missed last week's issue? See which articles your colleagues read most.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
